On December, 13 Spero Therapeutics, Inc. (SPRO) EPS Estimated At $-0.64

Spero Therapeutics, Inc. (NASDAQ:SPRO) Corporate Logo

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s earnings report is awaited on December, 13., Zacks reports. Last year’s earnings per share was $-36.02, while now analysts expect change of 98.22 % up from current $-0.64 earnings per share. -7.25 % EPS growth is what analysts predict. $-0.69 earnings per share was published for last quarter. Ticker’s shares touched $9.18 during the last trading session after 6.37% change.Spero Therapeutics, Inc. has volume of 46,333 shares. Since November 9, 2017 SPRO has 0.00% and is . SPRO underperformed the S&P 500 by 15.62%.

Spero Therapeutics, Inc. (NASDAQ:SPRO) Ratings Coverage

In total 3 analysts cover Spero Therapeutics (NASDAQ:SPRO). “Buy” rating has 2, “Sell” are 1, while 0 are “Hold”. 67% are bullish. 4 are the (NASDAQ:SPRO)’s analyst reports since May 11, 2018 according to StockzIntelligence Inc. In Friday, May 11 report H.C. Wainwright initiated the stock with “Buy” rating. On Thursday, May 10 the rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, October 16 the firm has “Underperform” rating by Bank of America given.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant bacterial infections in the United States.The company has $166.79 million market cap. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.Currently it has negative earnings.

For more Spero Therapeutics, Inc. (NASDAQ:SPRO) news announced briefly go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial” announced on November 05, 2018, “Spero Therapeutics receives QIDP designation for the development of SPR206” on October 11, 2018, “Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview” with a publish date: November 08, 2018, “New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero …” and the last “Mid-Day Market Update: Dow Rises Over 350 Points; Hanwha Q CELLS Shares Spike Higher” with publication date: October 16, 2018.

Spero Therapeutics, Inc. (NASDAQ:SPRO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.